CD28 and leukemia: This finding was consistent with our current findings that the CD19 CAR lentivirus-transduced CD3/CD28 Dynabead T cells mediate a greater anti-tumor response than do OKT3/IL-2 T cells in the same leukemia mouse model (Fig. 6E).